bioMérieux (OTCMKTS:BMXMF) Rating Lowered to “Hold” at Royal Bank of Canada

bioMérieux (OTCMKTS:BMXMF) was downgraded by investment analysts at Royal Bank of Canada from a “moderate buy” rating to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

bioMérieux Stock Performance

Shares of bioMérieux stock opened at $128.95 on Wednesday. The company has a quick ratio of 1.20, a current ratio of 2.21 and a debt-to-equity ratio of 0.10. The stock has a 50 day moving average price of $126.60 and a two-hundred day moving average price of $116.20. bioMérieux has a 12-month low of $93.50 and a 12-month high of $134.38.

bioMérieux Company Profile

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.